G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons
Acta Neuropathologica · 2024
DOI: 10.1007/s00401-023-02652-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Jeffrey D Rothstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. jrothstein@jhmi.edu. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Robert Packard Center for ALS Research, Johns Hopkins University, NIH NINDS/NIA.
Abstract (Originalsprache)
The G4C2 repeat expansion in the C9orf72 gene is the most common genetic cause of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Many studies suggest that dipeptide repeat proteins produced from this repeat are toxic, yet, the contribution of repeat RNA toxicity is under investigated and even less is known regarding the pathogenicity of antisense repeat RNA. Recently, two clinical trials targeting G4C2 (sense) repeat RNA via antisense oligonucleotide failed despite a robust decrease in sense-encoded dipeptide repeat proteins demonstrating target engagement. Here, in this brief report, we show that G2C4 antisense, but not G4C2 sense, repeat RNA is sufficient to induce TDP-43 dysfunction in induced pluripotent stem cell (iPSC) derived neurons (iPSNs). Unexpectedly, only G2C4, but not G4C2 sense strand targeting, ASOs mitigate deficits in TDP-43 function in authentic C9orf72 ALS/FTD patient iPSNs. Collectively, our data suggest that the G2C4 antisense repeat RNA may be an important therapeutic target and provide insights into a possible explanation for the recent G4C2 ASO clinical trial failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. jrothstein@jhmi.edu.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. jrothstein@jhmi.edu.
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
- Ionis Pharmaceuticals, Carlsbad, CA, 92010, USA.
- UK Dementia Research Institute at King's College London, London, UK.
ORCID-Profile: Alyssa N Coyne
Förderung
- NINDS NIH HHS
- Robert Packard Center for ALS Research, Johns Hopkins University
- NIH NINDS/NIA
- Target ALS
Zitieren
APA
Rothstein, J. D., Baskerville, V., Rapuri, S., Mehlhop, E., Jafar-Nejad, P., Rigo, F., Bennett, F., Mizielinska, S., Isaacs, A., & Coyne, A. N. (2024). G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons. Acta Neuropathologica. https://doi.org/10.1007/s00401-023-02652-3
Vancouver
Rothstein JD, Baskerville V, Rapuri S, Mehlhop E, Jafar-Nejad P, Rigo F, et al. G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons. Acta Neuropathologica. 2024. doi:10.1007/s00401-023-02652-3
BibTeX
@article{Rothstein2024,
author = {Rothstein, Jeffrey D and Baskerville, Victoria and Rapuri, Sampath and Mehlhop, Emma and Jafar-Nejad, Paymaan and Rigo, Frank and Bennett, Frank and Mizielinska, Sarah and Isaacs, Adrian and Coyne, Alyssa N},
title = {G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons},
journal = {Acta Neuropathologica},
year = {2024},
doi = {10.1007/s00401-023-02652-3}
}
EUVIMED